BELLUS Health Inc. (TSE:BLU – Get Free Report) shares passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$19.48 and traded as high as C$19.61. BELLUS Health shares last traded at C$19.48, with a volume of 28,666 shares trading hands.
BELLUS Health Stock Performance
The company has a debt-to-equity ratio of 0.32, a current ratio of 33.42 and a quick ratio of 16.40. The company’s 50 day moving average price is C$19.48. The stock has a market cap of C$2.47 billion, a P/E ratio of -20.29 and a beta of -0.28.
BELLUS Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Read More
- Five stocks we like better than BELLUS Health
- What is the Australian Securities Exchange (ASX)
- The Charles Schwab Company Can Hit New Highs
- Manufacturing Stocks Investing
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.
